| Literature DB >> 34037709 |
Shama Virani1, Glauco Baiocchi2, David Bowtell3, Citadel J Cabasag4, Kathleen R Cho5, Renée T Fortner6, Keiichi Fujiwara7, Jae-Weon Kim8, Martin Köbel9, Jean-Emmanuel Kurtz10, Douglas A Levine11, Usha Menon12, Barbara M Norquist13, Paul D P Pharoah14, Anil K Sood15, Shelley T Tworoger16, Nicolas Wentzensen17, Stephen J Chanock17, Paul Brennan1, Britton Trabert17.
Abstract
Recently, ovarian cancer research has evolved considerably because of the emerging recognition that rather than a single disease, ovarian carcinomas comprise several different histotypes that vary by etiologic origin, risk factors, molecular profiles, therapeutic approaches and clinical outcome. Despite significant progress in our understanding of the etiologic heterogeneity of ovarian cancer, as well as important clinical advances, it remains the eighth most frequently diagnosed cancer in women worldwide and the most fatal gynecologic cancer. The International Agency for Research on Cancer and the United States National Cancer Institute jointly convened an expert panel on ovarian carcinoma to develop consensus research priorities based on evolving scientific discoveries. Expertise ranged from etiology, prevention, early detection, pathology, model systems, molecular characterization and treatment/clinical management. This report summarizes the current state of knowledge and highlights expert consensus on future directions to continue advancing etiologic, epidemiologic and prognostic research on ovarian carcinoma. Published by Oxford University Press 2021.Entities:
Mesh:
Year: 2021 PMID: 34037709 PMCID: PMC8427725 DOI: 10.1093/carcin/bgab043
Source DB: PubMed Journal: Carcinogenesis ISSN: 0143-3334 Impact factor: 4.944